Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)19.50
  • Today's Change-0.41 / -2.06%
  • Shares traded22.01k
  • 1 Year change+11.36%
  • Beta0.8348
Data delayed at least 15 minutes, as of Oct 11 2024 17:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

  • Revenue in USD (TTM)610.81m
  • Net income in USD-41.97m
  • Incorporated2000
  • Employees1.97k
  • Location
    HUTCHMED (China) Ltd48Th Floor, Cheung Kong Center2 Queen's Road Central Hong KongHKG
  • Phone+852 21281188
  • Fax+852 21281778
  • Websitehttps://www.hutch-med.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amphastar Pharmaceuticals Inc712.89m166.52m2.25bn1.76k14.753.1810.263.163.143.1413.4514.570.49682.856.04404,821.7011.719.4213.5411.5654.6847.8323.5615.232.637.420.45150.0029.1416.9450.51---4.00--
Catalyst Pharmaceuticals Inc434.48m68.15m2.36bn167.0037.323.8822.565.440.53350.53353.715.140.75544.038.692,601,647.0011.8525.4213.5629.8186.6785.6315.6930.874.94--0.000.0085.90280.39-14.05--20.21--
Twist Bioscience Corp295.21m-220.31m2.44bn919.00--4.96--8.27-3.81-3.815.128.390.40765.428.56321,229.60-30.42-30.50-33.85-33.8440.5336.02-74.63-113.334.52--0.00--20.4157.336.08--49.76--
Amneal Pharmaceuticals Inc2.60bn-174.62m2.62bn7.70k----28.451.01-0.6224-0.622410.09-0.18570.72063.003.60337,401.60-3.69-4.80-4.93-5.9335.0434.76-5.13-9.000.81651.241.00--8.207.5635.38---6.55--
PTC Therapeutics, Inc.900.45m-479.52m2.96bn988.00------3.29-6.32-6.3211.84-12.750.55342.164.94911,390.70-29.47-26.71-44.23-33.4692.3593.94-53.25-83.802.17-1.161.70--34.2028.78-12.09--32.00--
Apellis Pharmaceuticals Inc628.79m-332.89m3.25bn702.00--12.28--5.16-2.74-2.745.152.170.69100.6693.03895,706.60-36.58-73.88-45.11-90.0386.38---52.94-326.494.18-17.870.6337--425.83--18.94------
Perrigo Company PLC4.43bn-113.90m3.31bn9.14k--0.727714.620.747-0.833-0.910632.3733.320.41462.485.78484,496.70-1.07-0.1148-1.21-0.131535.9335.28-2.57-0.29851.241.150.4717--4.58-0.323896.64---5.957.52
Prestige Consumer Healthcare Inc1.11bn205.13m3.39bn570.0016.742.0214.343.054.094.0922.1833.920.33463.096.751,952,965.006.173.696.423.8455.3256.7918.4312.191.905.260.39390.00-0.212.89354.34---1.84--
HUTCHMED (China) Ltd (ADR)610.81m-41.97m3.41bn1.97k--4.69--5.59-0.2497-0.24973.544.250.47757.104.15307,246.50-3.30---4.65--41.6736.57-6.91-31.442.68--0.0984--96.5231.38127.93--38.65--
ADMA Biologics Inc330.24m34.79m3.96bn624.00120.9721.0591.8812.010.14060.14061.410.80790.91811.049.88529,237.609.67-24.8010.99-28.0046.1217.4010.53-51.312.804.590.4105--67.5972.3457.15--18.91--
Axsome Therapeutics Inc291.49m-308.55m3.99bn545.00--38.61--13.68-6.51-6.516.152.150.50262.313.11534,842.20-53.20-64.55-71.90-82.2390.30---105.85-227.052.40-79.610.6409--440.80---27.84--77.86--
Organon & Co6.35bn1.00bn4.63bn10.00k4.6332.153.700.72953.893.8924.650.55930.54872.113.86634,600.008.6516.5311.1220.9758.5965.1215.7626.791.172.370.98368.251.44-8.5211.56-13.8320.91--
BridgeBio Pharma Inc219.12m-453.82m4.69bn550.00------21.42-2.64-2.641.24-5.810.3376----398,407.30-71.11-72.44-89.59-89.7298.9194.41-210.62-1,225.66---9.632.70---88.02---33.67---40.94--
Data as of Oct 11 2024. Currency figures normalised to HUTCHMED (China) Ltd's reporting currency: US Dollar USD

Institutional shareholders

4.80%Per cent of shares held by top holders
HolderShares% Held
Schroder Investment Management (Singapore) Ltd.as of 31 Mar 20241.98m1.14%
Schroder Investment Management (Hong Kong) Ltd.as of 31 Mar 20241.87m1.07%
Allianz Global Investors Asia Pacific Ltd.as of 31 Mar 20241.49m0.86%
Bellevue Asset Management AGas of 31 Mar 20241.15m0.66%
Acadian Asset Management LLCas of 30 Jun 2024389.12k0.22%
Millennium Management LLCas of 31 Mar 2024357.59k0.21%
SSgA Funds Management, Inc.as of 31 Mar 2024343.65k0.20%
AIA Investment Management Pte Ltd.as of 30 Jun 2024315.44k0.18%
Jane Street Capital LLCas of 31 Mar 2024275.23k0.16%
HSBC Bank Plc (Broker)as of 31 Mar 2024182.29k0.11%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.